Role of endothelial dysfunction, the interface between hemostatic and system inflammatory responses in the pathogenesis of an infectious inflammation-dependent exacerbation of chronic obstructive pulmonary disease

  • Authors: Tseĭmakh II.1, Momot AP2, Kostiuchenko GI3, Mamaev AN2,4, Filonova I.A1, Kornilova TA5, Chuchalin AG6
  • Affiliations:
    1. Алтайский государственный медицинский университет, Барнаул
    2. Алтайский филиал Гематологического научного центра Росздрава
    3. Алтайская краевая клиническая больница, Барнаул
    4. Алтайская краевая клиническая больница
    5. Городская больница №5, Барнаул
    6. НИИ пульмонологии ФМБА России, Москва
  • Issue: Vol 85, No 3 (2013)
  • Pages: 17-22
  • Section: Editorial
  • URL: https://journals.rcsi.science/0040-3660/article/view/31203
  • ID: 31203

Cite item

Full Text

Abstract

AIM: To analyze the systemic manifestations of vascular endothelial damage, the activation of hemostatic and inflammatory responses in patients with an infectious inflammation-dependent exacerbation of chronic obstructive pulmonary disease (COPD)/MATERIAL AND METHODS: The paper provides the data of examinations of 111 patients with the clinical signs of an infectious inflammation-dependent exacerbation of COPD who had 2 or 3 positive criteria elaborated by N. Anthonisen et al. (1987). The patients were divided into 2 phenotypically different subgroups: 1) 92 (82.9%) COPD patients without clinical manifestations of bronchoectasis; 2) 19 (17.1%) patients with COPD concurrent with documented bronchiectasis. The patient subgroups were matched for smoking status and the characteristics of COPD and respiratory failure. The investigators assessed the time course of changes in the serum level of endothelin-1 (ET-1), the aggregation function of platelets, and the plasma concentrations of D-dimers and homocysteine in patients with COPD compared to healthy, never smokers (n=35) and smokers (n=27)/RESULTS: An increase in the levels of the endothelial dysfunction markers ET-1 and homocysteine was found in patients with COPD, which was comparable with the changes in these indicators in the group of smokers. In both subgroups, the rise in plasma D-dimer levels was more pronounced in the patients with a COPD exacerbation than in the smokers. Its therapy with systemic and inhaled glucocorticosteroids reduced C-reactive protein and ET-1 levels in both patient subgroups and in D-dimers in subgroup 1. Elevated D-dimer levels remained when achieving remission, which points to the risk of thrombogenic and thromboembolic events in the patients with an infectious inflammation-dependent exacerbation of COPD and concomitant circulatory system diseases/CONCLUSION: The patients with an infectious inflammation-dependent exacerbation of COPD are observed to have elevated peripheral blood markers of endothelial dysfunction and thrombinemia. These changes are pathogenetically caused by smoking or neutrophilic inflammation and associated with a higher risk of thrombogenic events.

About the authors

I Ia Tseĭmakh

Алтайский государственный медицинский университет, Барнаул

Email: irintsei@rambler.ru

A P Momot

Алтайский филиал Гематологического научного центра Росздрава

G I Kostiuchenko

Алтайская краевая клиническая больница, Барнаул

A N Mamaev

Алтайский филиал Гематологического научного центра Росздрава; Алтайская краевая клиническая больница

Iu A Filonova

Алтайский государственный медицинский университет, Барнаул

T A Kornilova

Городская больница №5, Барнаул

A G Chuchalin

НИИ пульмонологии ФМБА России, Москва

References

  1. Шмелев Е.И. Хроническая обструктивная болезнь легких. В кн: Респираторная медицина. Под ред. А.Г. Чучалина. Руководство в 2 т. М: ГЭОТАР-Медиа 2007: 597-651.
  2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2009. www.goldcopd.org.
  3. Maio S., Baldacci S., Carrozzi L. et al. The global burden of chronic respiratory diseases. Eur Respir Rev 2006; 3: 21-29.
  4. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Часть I. ХОБЛ и поражения сердечно-сосудистой системы. Рус мед журн 2008; 2: 58-65.
  5. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J.2009; 33: 1165-1185.
  6. MacNee W., Maclay J., McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorax Soc 2008; 5: 824-833.
  7. Sin D.D., Man S.F. COPD as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorax Soc 2005; 2: 8-11.
  8. Anthonisen N.R., Connett J.E., Enright P.L. et al. Hospitalization and mortality in the Lung Helth Study. Am J Respir Crit Care Med 2002; 166: 333-339.
  9. Abdallah G.M., Abdullah A., Omran G.A., Mariee A.D. Serum homocystein level in COPD patients: possible beneficial effect of antioxidants. Res J Med and Med Sci 2009; 2920: 306-310.
  10. Gunen H., Gulbas G., In E. et al. Venous thromboembolism and exacerbations of COPD. Eur Respir J 2010; 35: 1243-1248.
  11. Polosa R., Cacciola R.R., Prosperini G. et al. Endothelial-coagulative activation during chronic obstructive pulmonary disease exacerbations. Haematol 2008; 93: 1275-1276.
  12. Parrillo J.E., Dellinger R.P. Critical care medicine: principals of diagnosis and management in the adult. Mosby 2002.
  13. Agusti A.G.N., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
  14. Mosesson M.W. Terminology for macromolecular derivatives of crosslinked fibrin. On behalf of the Subcommittee on Fibrinogen of the Scientific and Standardization Committee of the ISTH. Thrombos Haemostas 1995; 73: 725-726.
  15. Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита: Экспресс-издательство 2010.
  16. Мирошниченко И.И., Птицына С.Н., Кузнецова Н.Н., Калмыков Ю.М. Гомоцистеин - предиктор патологических изменений в организме человека. Рус мед журн 2009; 4: 224 -227.
  17. Шитикова А.С. Тромбоцитопатии, врожденные и приобретенные. СПб: ИИЦ ВМА 2008.
  18. Brotman D.J., Girod J.P., Garcia M.J. et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 2005; 90: 3202-3208.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies